1.10 0.00 (0.00%)
After hours: 4:48PM EDT
|Bid||1.03 x 1500|
|Ask||1.24 x 500|
|Day's range||1.07 - 1.12|
|52-week range||1.02 - 27.98|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.14|
Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. investors concerning the Company and its officers’ possible violations of federal securities laws.
Axovant Sciences made sweeping changes to its top ranks as the company struggles to regain its footing after abandoning its banner Alzheimer’s drug
Axovant Sciences Ltd. shares slid 21% in premarket trade Monday, after the company said Chief Executive David Hung and Chief Operating Officer Marion McCourt are leaving the company to pursue other opportunities. ...
Axovant Chief Operating Officer Marion McCourt and three directors on the company's board also stepped down. The departures come after Axovant stopped developing its lead drug, intepirdine, following the failure of two trials testing it as a treatment for Alzheimer's disease and dementia. "There is plenty of work to be done," incoming Axovant CEO Pavan Cheruvu said on a call with analysts.
Dr. David Hung resigns as CEO and continues as scientific advisor to Roivant family of companiesDr. Pavan Cheruvu appointed as CEO of AxovantDr. Roger Jeffs, former President and co-CEO of United Therapeutics, and George Bickerstaff, former CFO of Novartis Pharma, join board of directorsConference call today at 8:00 a.m. EST
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
The company flunked a mid-stage study testing the treatment on patients with dementia with Lewy bodies, three months after stopping the development of the drug, intepirdine, for treating Alzheimer's. Treatments for neurological disorders, like Alzheimer's and Parkinson's, could rake in blockbuster sales for drug developers but these drugs are expensive to develop and high failure rates have discouraged companies from pursuing their development. Pfizer Inc (PFE.N) said on Sunday it was abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease.
Last week, Vivek Ramaswamy's biggest bet, on the Alzheimer's drug being developed by Axovant Sciences, failed. This morning, one of his smaller ones came through: a treatment for uterine fibroids being tested by Myovant, another company started by Ramaswamy's vehicle, Roivant.